Type I Interferon Signature is Associated With Lung Disease, Drug‐Associated Immune Reactions, and Genetic Variation in Interferon‐Linked Pathways in Still Disease

Authors:
Publisher website
Google Scholar
Abstract
Objective: To evaluate the relationship across type I interferon (IFN‐I)–stimulated gene (ISG) expression, Still disease, and the development of lung disease (LD) and drug‐associated immune reactions (DAIR) to interleukin‐1 (IL‐1) and/or IL‐6 inhibitors. Methods: Whole blood ISG expression was quantified by NanoString array. ISG‐28 scores were calculated in consecutive patients with Still or Still‐like disease. Exome sequencing with family‐based variant prioritization identified candidate genes harboring rare candidate causative variants. Lists of candidate genes were subjected to functional enrichment analysis. Results: Among 57 patients (32 children, 25 adults), 16 had elevated ISG‐28 scores. This group exhibited higher prevalence of LD (0.44 vs 0.1, P = 0.007) and DAIR (0.63 vs 0.17, P = 0.003) and lower IL‐6 inhibitor use (0 vs 0.25, P = 0.048) compared to others. No significant differences were found in the rates of macrophage activation syndrome, active disease, elevated IL‐18, or current IL‐1 inhibition. The combination of HLA‐DRB1*15 with high ISG‐28 scores is associated with LD and DAIR with high specificity, whereas absence of both biomarkers had high negative predictive value. Candidate genes from high ISG‐28 individuals were enriched in IFN‐related pathways, including autophagy, IFN‐I production, toll‐like receptor signaling, macrophage activation, cytoskeletal organization, and responses to stress. Conclusion: High IFN‐I expression correlates with LD and DAIR in Still disease, linked to rare genetic variation in immune pathways. Combining high ISG‐28 with HLA‐DRB1*15 significantly improves post hoc stratification of patients for these complications. If prospectively validated, these findings may guide molecular risk assessment and targeted therapies, including IFN‐I directed treatments in Still disease with IFN‐I signature.
Funding Information
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (Z01‐AR‐041198)

This publication has 57 references indexed in Scilit: